English
English French German Portuguese Spanish Russian Japanese Korean Arabic Irish Greek Turkish Italian Danish Romanian Indonesian Czech Afrikaans Swedish Polish Basque Catalan Esperanto Hindi Lao Albanian Amharic Armenian Azerbaijani Belarusian Bengali Bosnian Bulgarian Cebuano Chichewa Corsican Croatian Dutch Estonian Filipino Finnish Frisian Galician Georgian Gujarati Haitian Hausa Hawaiian Hebrew Hmong Hungarian Icelandic Igbo Javanese Kannada Kazakh Khmer Kurdish Kyrgyz Latin Latvian Lithuanian Luxembou.. Macedonian Malagasy Malay Malayalam Maltese Maori Marathi Mongolian Burmese Nepali Norwegian Pashto Persian Punjabi Serbian Sesotho Sinhala Slovak Slovenian Somali Samoan Scots Gaelic Shona Sindhi Sundanese Swahili Tajik Tamil Telugu Thai Ukrainian Urdu Uzbek Vietnamese Welsh Xhosa Yiddish Yoruba Zulu Kinyarwanda Tatar Oriya Turkmen Uyghur
Leave Your Message
Tetrahydrocurcumin
Natural API
Tetrahydrocurcumin.jpg
Curcuma longa.jpg

Tetrahydrocurcumin

Tetrahydrocurcumin (CAS: 36062-04-1) is the primary metabolite of curcumin and a reduced form of the active component found in turmeric (Curcuma longa). With ​superior antioxidant, anti-inflammatory, and neuroprotective​ activity compared to curcumin, it was designated as GRAS (Generally Recognized as Safe) by the FDA in 2023 and approved as a food antioxidant (E 100(iii)) by the European EFSA. China's National Health Commission included it in the food additive directory (GB 2760-2022) in 2022.

Product Name: Tetrahydrocurcumin

IUPAC Name: (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-4-heptadione

CAS No.​: 36062-04-1

    Contact us
    product details
    product description

    description1

    description2

    Tetrahydrocurcumin

    Basic information

    Product Name: Tetrahydrocurcumin

    IUPAC Name: (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-4-heptadione

    CAS No.​:  36062-04-1

    Molecular Formula: C₂₁H₂₄O₆

    Physicochemical Properties:

    Parameter

    Value/Description

    ​Appearance​

    White to pale yellow powder

    ​Melting Point​

    83–85°C

    ​Solubility​

    0.1 mg/mL in water; >50 mg/mL in DMSO

    ​logP​

    3.2 (moderate lipophilicity)

    ​pKa​

    8.5 (phenolic OH), 10.2 (enolic OH)

    ​Stability​

    Light-sensitive; most stable at pH 6–8

    Quality Standard: CP2020,JP,Customer Made

    Specification

    Test Items

    Standard

    Tetrahydrocurcumin (CAS: 36062-04-1)

    98% by HPLC

    Loss on drying

    ≤0.5%

    Residue on ignition

    ≤0.1%

    Key Features

    index_10-7

    Metabolic Advantage

     80% oral bioavailability (vs. 1% for curcumin).
    index_10-7

    Multi-Target Action

    Simultaneously activates Nrf2 while inhibiting NF-κB and COX-2.
    index_10-7

    High Safety

    NOAEL (No Observed Adverse Effect Level) = 500 mg/kg/day.

    Pharmacological Mechanisms

    1.Molecular Target Network

    Pharmacological Mechanisms

    2.Pharmacokinetics

    Absorption

    80% oral bioavailability (low glucuronidation).

    Distribution

    High in liver and brain (brain/plasma ratio=1.8:1).

    Metabolism

    Hepatic CYP2D6-mediated methylation (active metabolites).

    Excretion

    Primarily biliary (90% clearance in 72h).

    Clinical Applications

    Indications & Protocols​

    Condition​

    ​Regimen​

    ​Evidence​

    ​Osteoarthritis​

    200 mg/day ×12 weeks

    ↓35% WOMAC score*

    ​Melasma​

    2% cream bid ×8 weeks

    ↓50% MASI score

    ​Mild Cognitive Impairment​

    100 mg bid (Phase II)

    ↑2 MMSE points

    *Multicenter RCT (n=300)

    Special Populations​

    Hepatic Impairment: Reduce dose 50% (Child-Pugh B).

    Elderly: No dose adjustment (monitor blood pressure).

    Dosage and Administration

    Formulations​
    Softgel Capsules: 100 mg/capsule (MCT oil carrier).
    Topicals: 1–3% serums/creams.
    Injection: 20 mg/mL (dilute in saline).

    Dosing Guidelines

    Use​

    ​Dose​

    ​Duration​

    ​Anti-Inflammatory​

    200–400 mg/day

    8–12 weeks

    ​Skin Brightening​

    Topical bid

    ≥8 weeks

    ​Neuroprotection​

    100–200 mg/day

    Long-term

    Safety Evaluation

    Adverse Reactions

    System​

    ​Incidence​

    ​Manifestations​

    ​Gastrointestinal​

    2%

    Mild diarrhea

    ​Dermatologic​

    0.5%

    Contact dermatitis

    ​Hepatic​

    <0.1%

    Reversible ALT↑

    Contraindications & Interactions​

    Absolute CI:
    Curcuminoid allergy.
    Complete biliary obstruction.

    Cautions:CYP2D6 substrates (e.g., metoprolol): May ↑30% plasma concentration.

    Research Progress Green max

    Novel Formulations​

    Nanostructured Lipid Carriers: ↑15× transdermal absorption.

    Sustained-Release Microspheres: Single injection maintains efficacy for 7 days.

    New Indications

    Diabetic Nephropathy: Inhibits TGF-β1/Smad3 (↓40% fibrosis in animals).

    Parkinson’s Disease: Protects dopaminergic neurons (↑35% TH+ cells in MPTP models).

    Curcuma longa

    Please Send me email and you can get more what you want.

    Such as product of  Price, Specification, MOA, MSDS, Flow Chart, Packing details, Shipping Term, Payment Term, after Sale service and so on.

    Our experts will solve them in no time.